Gene transfer for the therapy of hematologic malignancy
- PMID: 9372030
- DOI: 10.1097/00062752-199502060-00004
Gene transfer for the therapy of hematologic malignancy
Abstract
Gene transfer has allowed a number of biologic issues in the therapy of hematologic malignancy to be addressed. In autologous bone marrow transplantation, gene marking studies have shown that infused marrow contributes to relapse in acute myeloid leukemia, neuroblastoma, and chronic myeloid leukemia. In addition, double gene marking with distinguishable retroviral vectors has allowed comparison of purging techniques and the ability of different sources of stem cells to repopulate. In allogeneic bone marrow transplantation, genetically modified T cells have proven valuable for the prophylaxis and treatment of viral diseases and may be of use to treat disease relapse. Gene transfer is also being used to modify tumor function, enhance immunogenicity, modify function of adoptively transferred immune system cells, and confer drug resistance to normal hematopoietic stem cells.
Similar articles
-
Gene-marking and haemopoietic stem-cell transplantation.Blood Rev. 1995 Dec;9(4):220-5. doi: 10.1016/s0268-960x(95)90013-6. Blood Rev. 1995. PMID: 8839397 Review.
-
Use of gene marking in bone marrow transplantation.Cancer Detect Prev. 1996;20(2):108-13. Cancer Detect Prev. 1996. PMID: 8706035
-
Gene marking to improve the outcome of autologous bone marrow transplantation.J Hematother. 1994 Spring;3(1):33-6. doi: 10.1089/scd.1.1994.3.33. J Hematother. 1994. PMID: 7922006
-
Gene therapy for paediatric leukaemia.Expert Opin Biol Ther. 2001 Jul;1(4):663-74. doi: 10.1517/14712598.1.4.663. Expert Opin Biol Ther. 2001. PMID: 11727502 Review.
-
[Contribution of antineoplastic biotherapy in the treatment of leukemia in children].Arch Pediatr. 2002 Mar;9(3):289-306. doi: 10.1016/s0929-693x(01)00767-9. Arch Pediatr. 2002. PMID: 11938542 Review. French.
Cited by
-
Gene therapy in pediatric oncology.Invest New Drugs. 1996;14(1):87-99. doi: 10.1007/BF00173685. Invest New Drugs. 1996. PMID: 8880396 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources